Search Within

Joachim Yahalom

  1. "Miguel-Angel Perales"
Formats
  1. Meeting Abstract (21)
  2. Journal Article (12)
  3. Research Letter (1)
Groups
  1. Bone Marrow Transplant (34)
  2. Center for Hematologic Malignancies (34)
  3. Department of Medicine (34)
  4. Hematologic Malignancies, Division of (34)
  5. Radiation Oncology, Department of (34)
  6. Survivorship Research (34)

More Groups

People
  1. Miguel-Angel Perales (34)
  2. Maria Palomba (30)
  3. Gunjan Shah (25)
  4. Parastoo Dahi (25)
  5. Brandon Imber (24)
  6. Michael Scordo (23)

More People

Years
  1. 2025 (1)
  2. 2024 (5)
  3. 2023 (6)
  4. 2022 (4)
  5. 2021 (3)
  6. 2020 (3)

More Years

Publications
  1. Blood (11)
  2. Hematological Oncology (4)
  3. International Journal of Radiation Oncology, Biology, Physics (4)
  4. Transplantation and Cellular Therapy (3)
  5. Blood Advances (2)
  6. British Journal of Haematology (2)

More Publications

Publishers
  1. American Society of Hematology (13)
  2. Elsevier Inc. (8)
  3. Wiley Blackwell (4)
  4. John Wiley & Sons (2)
  5. Nature Publishing Group (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (34)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies
    Journal Article

    Sermer, D.; Batlevi, C.; Lia Palomba, M.; Shah, G.; Lin, R. J.; Perales, M. A.; Scordo, M.; Dahi, P.; Pennisi, M.; Afuye, A.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy
    Journal Article

    Imber, B. S.; Sadelain, M.; DeSelm, C.; Batlevi, C.; Brentjens, R. J.; Dahi, P. B.; Giralt, S.; Park, J. H.; Sauter, C.; Scordo, M.; more...
    British Journal of Haematology (2020)

    Fulltext@MSK | Save
  • Long-term follow-up confirms durability of single-agent brentuximab vedotin as pre-transplant salvage for classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Schoder, H.; Lee, J.; Davey, T.; Hancock, H.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; Noy, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Early experience using radiotherapy as a salvage treatment for relapsed or refractory non-Hodgkin lymphomas following CD19 chimeric antigen receptor modified T-cell therapy
    Meeting Abstract

    Imber, B.; Palomba, M. L.; DeSelm, C.; Dahi, P. B.; Sauter, C. S.; Scordo, M.; Batlevi, C. L.; Park, J. H.; Shah, G. L.; Giralt, S. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • MSKCC early experience using radiotherapy as a bridging strategy for relapsed diffuse large B cell lymphoma before CD19 CAR T therapy
    Meeting Abstract

    Imber, B.; Palomba, M. L.; DeSelm, C.; Batlevi, C. L.; Dahi, P. B.; Giralt, S. A.; Noy, A.; Park, J. H.; Sauter, C. S.; Scordo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • MSKCC early experience using radiotherapy as a bridging strategy for relapsed diffuse large B cell lymphoma before CD19 CAR T therapy
    Meeting Abstract

    Imber, B. S.; Palomba, M. L.; DeSelm, C.; Batlevi, C.; Dahi, P. B.; Giralt, S.; Noy, A. M.; Park, J. H.; Sauter, C. S.; Scordo, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation
    Journal Article

    Hobbs, G. S.; Kaur, N.; Hilden, P.; Ponce, D.; Cho, C.; Castro-Malaspina, H. R.; Giralt, S.; Goldberg, J. D.; Jakubowski, A. A.; Papadopoulos, E. B.; more...
    Bone Marrow Transplantation (2016)

    Fulltext@MSK | Save